Immunicon : Immunicon Congratulates Dr. Daniel Hayes on Winning ASCO's Inaugural Gianni Bonadonna Breast Cancer Award
09/11/2007| 09:50am US/Eastern
Recommend:
Immunicon Corporation (NASDAQ-GM:IMMC) congratulates Daniel F. Hayes,
MD, professor of internal medicine and Clinical Director of the Breast
Oncology Program at the University of Michigan Comprehensive Cancer
Center, for receiving the inaugural American Society of Clinical
Oncology (ASCO) and The ASCO Foundation's Gianni Bonadonna Breast Cancer
Award and Fellowship. The annual $10,000 award, presented at the
September 7-8 Breast Cancer Symposium in San Francisco, recognizes an
active clinical or translational researcher with a distinguished record
of accomplishments in advancing the field of breast cancer.
Among his many research accomplishments, Dr. Hayes has been a major
force in the clinical application of the CellSearch?
Circulating Tumor Cell Test, developed by Immunicon Corporation and
marketed by Veridex LLC, a Johnson & Johnson company. In 2004, his
research was among those published in The New England Journal of
Medicine that had a direct impact on CellSearch's FDA Clearance. Dr.
Hayes continues to conduct clinical trials and research to discover how
best to integrate the knowledge gained from leveraging circulating tumor
cells in the treatment of patients with metastatic breast cancer.
Byron D. Hewett, President and Chief Executive Officer of Immunicon
commented, ?Dr. Hayes has been a pioneering
force in circulating tumor cell research. His leadership in clinical
trials is helping to translate this important technology to the clinical
setting.?
The Gianni Bonadonna Award is accompanied by a one-year, $50,000
Fellowship Grant that will be awarded by The ASCO Foundation to an
early-career breast cancer researcher who will work in the lab at the
recipient's institution. ASCO is the world's leading professional
organization representing physicians of all oncology subspecialties who
care for people with cancer. For more about the award, visit www.asco.org.
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary
cell- and molecular-based human diagnostic and life science research
products with an initial focus on cancer disease management. Immunicon
has developed platform technologies for selection and analysis of rare
cells in blood, such as circulating tumor cells and circulating
endothelial cells that are important in many diseases and biological
processes. Immunicon's products and underlying
technology platforms also have application in the clinical development
of cancer drugs and in cancer research and may have applications in
other fields of medicine, such as cardiovascular and infectious
diseases. For more information, please visit www.immunicon.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are often preceded by words such as ?hope,?
?may,? ?believe,?
?anticipate,? ?plan,?
?expect,? ?intend,?
?assume,? ?will?
and similar expressions. Forward-looking statements contained in this
press release include, among others, statements regarding the
anticipated clinical utility of Immunicon's
products and services and other statements not of historical fact.
Immunicon cautions investors not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release, are based on the current expectations and intent of the
management of Immunicon and involve certain factors, such as risks and
uncertainties that may cause actual results to be far different from
those suggested by these statements. These statements are not guarantees
of future performance and involve risks and uncertainties that are
difficult to predict, including, but not limited to, risks and
uncertainties associated with: Immunicon's
dependence on Veridex, LLC, a Johnson & Johnson company, in the field of
cancer cell analysis; the ability to earn license and milestone payments
under Immunicon's agreement with Veridex;
Immunicon's capital and financing needs;
research and development and clinical trial expenditures;
commercialization of product candidates; Immunicon's
ability to obtain licenses from third parties to commercialize products;
Immunicon's ability to manage its growth;
obtaining necessary regulatory approvals; reliance on third party
manufacturers and suppliers; reimbursement by third party payors to
Immunicon's customers; compliance with
applicable manufacturing standards; retaining key personnel; delays in
the development of new products or planned improvements to products;
effectiveness of products compared to competitors'
products; protection of Immunicon's
intellectual property; conflicts with third party intellectual property;
product liability lawsuits that may be brought against Immunicon; labor,
contract or technical difficulties; and competitive pressures in
Immunicon's industry. These factors are
discussed in more detail in Immunicon's
filings with the Securities and Exchange Commission. Except as required
by law, Immunicon accepts no responsibility for updating the information
contained in this press release beyond the published date, whether as a
result of new information, future events or otherwise, or for
modifications made to this document by Internet or wire services.
?Immunicon? and
the Immunicon Corporation logo are registered trademarks of Immunicon
Corporation. ALL RIGHTS RESERVED.
Immunicon Corporation
James G. Murphy
SVP of Finance &
Administration, CFO
215-346-8313
jmurphy@immunicon.com
or
Investors/Media:
Tierney Communications
Denise Portner
Vice President
215-790-4395
dportner@tierneyagency.com
© Business Wire 2007
Recommend :
